Skip to main content

Radiation & Tissue Effects in the Genitourinary Tract

Pelvic radiotherapy can produce acute mucosal symptoms and delayed urinary, bowel and sexual dysfunction. Severity depends on the treated volume, dose distribution, fractionation, baseline function and other treatments. Some effects resolve; others persist or appear years later. A radiation history increases reconstructive risk but does not establish that every tissue is nonviable or that a graft or anastomosis will fail.[1][2]

This page covers tissue effects and their implications for functional reconstruction. For occupational fluoroscopy protection, see Radiation Safety.

What Radiation Changes​

Acute effects usually develop during or soon after treatment and often improve over the following weeks. Late injury can emerge months to years later, including after a relatively mild acute course. Studies use different cutoffs for “late” toxicity; retain each study's definition when comparing outcomes.[1]

Tissue processReconstructive implication
Mucosal injury and altered barrier functionDysuria, urgency, pain and bleeding require evaluation for other causes as well as treatment effects
Microvascular injury, telangiectasia and impaired perfusionFragile bleeding surfaces and less reliable healing in affected areas
Fibrosis, extracellular matrix remodeling and cellular senescenceReduced compliance, narrowed lumens and difficult dissection planes
Neuromuscular and endocrine effects, alongside vascular injuryUrinary, bowel and sexual symptoms may have several contributors

These processes vary within the treatment field. The familiar hypovascular, hypocellular, hypoxic description is a warning about compromised tissue, not a test of viability. Preserve useful vascular supply and judge the actual defect and recipient bed. Experimental changes in urothelial proteins or matrix stiffness should not be treated as validated human prognostic tests.[1][2]

Interpreting the Major Evidence​

EBRT is a delivery category; IMRT/VMAT describe dose delivery techniques, and SBRT describes a highly hypofractionated approach. These terms overlap. Brachytherapy, postoperative radiation and combined treatments have different populations and dose distributions. Obtain the actual treatment record rather than assigning a risk from the modality name alone.[1][3]

StudyFinding relevant to functional counselingEssential limitation
ASCENDE-RT morbidity analysis, 2017Five-year cumulative grade 3 GU events were 18.4% after LDR brachytherapy boost versus 5.2% after dose-escalated EBRT boostThese are not stricture rates. Both groups received pelvic RT and androgen deprivation. Morbidity was analyzed in 383 patients according to treatment received after exclusions and crossover adjustment.[4]
PACE-B, 2024In 874 randomized men, five-fraction SBRT was noninferior for biochemical/clinical control, but cumulative late RTOG grade ≥2 GU toxicity through five years was 26.9% versus 18.3% with conventional/moderate hypofractionationTrial-specific low/intermediate-risk eligibility; no androgen deprivation. Cumulative events differ from symptoms present at the five-year visit: RTOG grade ≥2 GU toxicity at that visit was 26/355 versus 16/355.[5]
PACE-B patient-reported outcomes, 2026At five years, pad-free rates were 233/257 (91%) after SBRT and 225/250 (90%) after control RTThese are respondents to that item, not all 874 randomized men; pad-free is not leak-free. This follow-up does not negate the earlier cumulative toxicity difference.[6]
ProtecT, 12-year patient-reported follow-up, 2023During years 7–12, pad use was 18–24% after allocation to prostatectomy, 3–8% after RT with neoadjuvant androgen deprivation, and 9–11% with active monitoringAnalysis retained randomized groups, including later treatment changes. RT used the trial's earlier treatment protocol. Urinary leakage, voiding symptoms, sexual function and bowel effects follow different trajectories.[7]

Do not translate a toxicity grade into a different outcome. RTOG/EORTC and CTCAE grades are not interchangeable, and CTCAE definitions depend on the adverse-event term and version. Distinguish clinician grading from patient-reported bother, a cumulative event from point prevalence, and a composite GU endpoint from stricture or incontinence alone.[5][8]

The 2023 IMRT meta-analysis illustrates why denominators matter: its pooled RTOG and CTCAE estimates came from different subsets, and its urinary-retention estimate rested on only ten participants. Those figures should not be used as a universal complication table for contemporary pelvic RT.[9]

Assessment Before Attributing Symptoms to Radiation​

Record the radiation target, modality, timing, fractionation and available dose plan; prior pelvic operations, instrumentation and systemic therapy; baseline and current urinary, bowel and sexual function; and the patient's priorities. New symptoms can reflect infection, recurrent cancer, a second malignancy, obstruction, stones or other disease.[2][8]

  • Hematuria: assess severity, clots, retention and hemodynamic status. Investigate the urinary tract with laboratory testing, appropriate upper-tract imaging and cystoscopy; biopsy lesions concerning for malignancy. Anticoagulation or a radiation history does not establish the cause.[8]
  • Weak stream or retention: define the level and extent of obstruction, bladder function and upper-tract consequences before further instrumentation. Bulbomembranous stricture is a characteristic post-prostate-RT problem; necrosis, calcification and fistula change the management pathway.[2]
  • Storage symptoms or incontinence: separate impaired storage, poor emptying and sphincter dysfunction. Symptom-directed medication and pelvic-floor care must follow that assessment; they do not treat a fixed stricture or restore a severely fibrotic reservoir.[2][3]

Radiation is associated with later second cancers, but absolute risks depend on population, treatment and follow-up. A Medicare-linked observational study's hazard ratio of 2.76 concerned a combined urinary/sexual complication endpoint, not urinary incontinence alone. Its associations are not randomized estimates of the causal effect of radiation. New hematuria prompts diagnostic evaluation, not an assumption that routine surveillance cystoscopy is indicated for every asymptomatic irradiated patient.[8][10]

Hemorrhagic Radiation Cystitis​

Treatment depends on bleeding severity, renal function, bladder condition and access to expertise. The CUA framework separates initial care, persistent/recurrent bleeding and refractory life-threatening bleeding; it does not require every patient to pass through a fixed sequence.[8]

Clinical situationApproach
Clots, retention or significant ongoing bleedingStabilization, drainage/irrigation, clot evacuation and cystoscopic assessment with treatment of bleeding sites as appropriate
Persistent or recurrent clinically significant bleedingConsider alum, HBOT or selected other bladder-directed treatments according to urgency and suitability. Alum requires particular caution with impaired renal function; hyaluronic acid has slower onset and limited evidence in severe acute bleeding.
Refractory or life-threatening bleedingConsider selective/superselective embolization and specialist salvage options. Formalin is reserved for failure of less invasive treatment because of substantial morbidity; exclude perforation and prevent upper-tract exposure.
Devastated bladder or unsuccessful salvageDiscuss diversion with or without cystectomy, including the substantial operative risk and possible complications of a retained bladder.

The above is a decision framework; intravesical concentrations and administration belong in the relevant drug/procedure protocol.[8]

Hyperbaric Oxygen: What the Trials Establish​

RICH-ART's original open-label randomized comparison, published in 2019, found greater improvement in urinary symptom scores with HBOT than standard care. The 2025 report follows treated patients after the control group was offered HBOT; it is not a five-year randomized untreated comparison.[11][12]

Among 70 patients entering long-term follow-up, the mixed-model estimated improvement in EPIC urinary total score at five years was 19.1 points (95% CI 13.3–24.9). Only 39 had actual five-year observations, with 31/70 missing at that visit; 9/70 received additional HBOT for recurrence. The study excluded patients with bleeding requiring transfusion exceeding 500 mL within the preceding four weeks, a permanent catheter for incontinence, bladder capacity below 100 mL, or bladder fistula. Its findings therefore do not establish HBOT as emergency hemostasis or treatment of a devastated outlet/fistula.[12]

The 2023 Cochrane review supports possible benefit for selected late radiation injuries, with uncertainty about patient selection, timing and dose. Results from different irradiated organs should not be transferred wholesale to bladder reconstruction. See Hyperbaric Oxygen Therapy for treatment selection and safety.[13]

Reconstructive Planning​

The goals are durable drainage, a usable reservoir, acceptable continence and relief of pain or infection. Evaluate these together before committing to outlet reconstruction. A patent urethra alone may not help a patient with severe bladder pain, poor capacity/compliance or fistulation.[2]

Urethra and Outlet​

For radiation-induced bulbomembranous strictures refractory to endoscopic treatment, EAU 2026 allows EPA or augmentation urethroplasty for short strictures below 2.5 cm, selected to anatomy and expertise, and recommends augmentation for longer strictures. Counsel about new incontinence and erectile dysfunction. The guideline's pooled patency estimate of approximately 80% comes from limited observational evidence; absence of a significant difference between techniques does not prove equivalence.[2]

In Rourke's 35-patient cohort, 85.7% patency applied to the whole group, comprising 23 EPA, seven buccal-graft and five flap repairs. It was not an EPA-only rate. Adverse changes in continence and erectile function were reported, reinforcing the need to distinguish anatomical patency from functional success.[14]

A vascularized flap can provide coverage or interposition when indicated by the defect, tissue quality or fistula. It is not mandatory for every irradiated urethroplasty, and a free mucosal graft remains dependent on an adequate recipient bed. Extensive necrosis, intolerable bladder dysfunction or repeated unsuccessful reconstruction may favor supravesical diversion.[2]

See Urethral Stricture and Urethral Reconstruction Principles.

Ureter and Bladder​

Define stricture location and length, renal function and available healthy tissue. A bladder-based repair requires a bladder that can be mobilized and used safely; prior RT may limit its capacity or reach. Reimplantation, graft-based repair and bowel substitution are selected according to those findings. Vascularized coverage may be helpful, but neither an omental wrap nor a robotic approach guarantees success.[15]

The reported 88.2% success in the collaborative robotic radiation-stricture series was 30/34 ureteral units with follow-up, after one early death was excluded from 35 treated units in 32 patients. This selected, short-follow-up series does not demonstrate superiority over open repair or define a universal reconstruction ladder.[15]

Diversion decisions should account for the outlet, bladder, fistula/necrosis, pain, renal function, prior bowel exposure and surgical fitness. Rates of diversion in tertiary-referral cohorts of severe radiation injury are not the probability that an average RT recipient will need diversion.[2][8]

See Ureteral Stricture and Urinary Diversion Principles.

Pelvic Floor and Sexual Function​

Women​

Ask about urgency, leakage, bowel symptoms, vaginal dryness, pain, bleeding and sexual goals. Examination and multidisciplinary care can identify mucosal, muscular, endocrine and structural contributors rather than attributing every symptom to fibrosis.

A 2026 systematic review included 15 observational studies and 1,667 women treated with pelvic RT, with prior pelvic surgery or rehabilitation excluded by its eligibility criteria. Urinary incontinence was pooled from nine studies/805 women: 37% (95% CI 27–47%), with substantial heterogeneity. The separate 47% urgency-incontinence estimate came from five studies/305 women; it is not a subgroup percentage within the 37%. Differences in populations, assessments and treatment eras limit use for individual prediction.[16]

Vaginal mucosal injury, stenosis and ovarian dysfunction may contribute to dyspareunia and dryness. Lubricants/moisturizers, individualized pelvic-floor therapy and discussion of vaginal dilation after acute injury has settled can support recovery and examination access. Dilation should be comfortable and individualized; the Cochrane review did not establish a preventive benefit from reliable comparative trials. Hormonal treatment requires assessment of the cancer type, treatment and individual suitability rather than a blanket post-RT prescription.[17][18]

Men​

Sexual recovery reflects baseline function, age, vascular/neural injury, androgen deprivation and subsequent treatment. In ProtecT, erections adequate for intercourse at seven years were reported by 27% of the RT group, 18% of the prostatectomy group and 30% of the active-monitoring group; function declined in all groups and converged to low levels by twelve years. These are outcomes by randomized allocation, not a prediction for an individual contemporary RT regimen.[7]

Treat established ED according to function, contraindications and patient preference. Treatment of ED and prevention of ED are different questions: the placebo-controlled RTOG 0831 trial did not show that daily tadalafil during and after RT preserved spontaneous erectile function. Do not promise that prophylactic PDE5 inhibitors prevent radiation injury.[19]

Long-term care should revisit urinary, bowel and sexual symptoms and their impact on daily life. Major trials show changing trajectories across domains; neither inevitable progression nor spontaneous resolution is a reliable universal prognosis.[5][7]

References​

1. Citrin DE, Timmerman RD. Effects of radiotherapy in normal tissue. N Engl J Med. 2026;394:996–1009. DOI

2. European Association of Urology. EAU Guidelines on Urethral Strictures. 2026. Disease management in males, radiation/high-energy induced posterior strictures and urinary diversion. Guideline

3. Martin JM, Richardson M, Siva S, et al. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. Lancet Oncol. 2022;23:e534–e543. PMID 36455582

4. Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98:286–295. DOI

5. van As N, Griffin C, Tree A, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024;391:1413–1425. DOI

6. Cooper S, Patel J, Moore C, et al. Patient-reported outcomes after prostate stereotactic body radiotherapy at 5 yr: results from the PACE-B trial. Eur Urol. 2026. DOI

7. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid. 2023;2. DOI

8. Goucher G, Saad F, Lukka H, Kapoor A. Canadian Urological Association Best Practice Report: diagnosis and management of radiation-induced hemorrhagic cystitis. Can Urol Assoc J. 2019;13:15–23. DOI

9. David R, Buckby A, Kahokehr AA, et al. Long-term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:8–15. PMID 35260794

10. Unger JM, Till C, Tangen CM, et al. Long-term adverse effects and complications after prostate cancer treatment. JAMA Oncol. 2024. DOI

11. Oscarsson N, Müller B, Rosén A, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. Lancet Oncol. 2019;20:1602–1614. DOI

12. Oscarsson N, Rosén A, Müller B, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): long-term follow-up of a randomised controlled, phase 2–3 trial. EClinicalMedicine. 2025;83:103214. DOI

13. Lin ZC, Bennett MH, Hawkins GC, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2023;8:CD005005. DOI

14. Rourke K, Kinnaird A, Zorn J. Observations and outcomes of urethroplasty for bulbomembranous stenosis after radiation therapy for prostate cancer. World J Urol. 2016;34:377–382. PMID 26047655

15. Asghar AM, Lee Z, Lee RA, et al. Robotic ureteral reconstruction in patients with radiation-induced ureteral strictures: experience from the Collaborative of Reconstructive Robotic Ureteral Surgery. J Endourol. 2021;35:144–150. PMID 32814443

16. Pérez CDA, Rocha AKL, Volpato MP, et al. Prevalence of pelvic floor dysfunction in women after pelvic radiotherapy: systematic review and meta-analysis. Int Urogynecol J. 2026. DOI

17. Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev. 2014;9:CD007291. PMID 25198150

18. Hickey M, Basu P, Sassarini J, et al. Managing menopause after cancer. Lancet. 2024;403:984–996. PMID 38458217

19. Pisansky TM, Pugh SL, Greenberg RE, et al. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA. 2014;311:1300–1307. DOI